In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ArQule gets $75mm up front in two new deals with Daiichi; certain rights returned to ArQule

Executive Summary

ArQule (oncology therapeutics) and Daiichi Sankyo (Japanese pharmaco developing treatments for cardiovascular diseases, diabetes, autoimmune disorders, cancer, and infections) have entered into two cancer deals that together provide ArQule with $75mm up front and the potential for up to $560mm in milestones.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies